Cordycepin augments the chemosensitivity of osteosarcoma to cisplatin by activating AMPK and suppressing the AKT signaling pathway

• Published in: Cancer cell international Vol. 21; no. 1; p. 706
• Main Authors: Li, Hong-Bo, Chen, Jun-Kai, Su, Ze-Xin, Jin, Qing-Lin, Deng, Li-Wen, Huang, Gang, Shen, Jing-Nan
• Format: Journal Article
• Language: English
• Published: England BioMed Central 25.12.2021; BMC
• Subjects: AKT; AKT protein; AMPK; Animal models; Antitumor activity; Apoptosis; Bone cancer; Bone tumors; Cell culture; Cell proliferation; Chemotherapy; Cholecystokinin; Cisplatin; Colonies; Cordycepin; Drug resistance; Ethanol; Experiments; Flow cytometry; Medical prognosis; Osteosarcoma; Osteosarcoma cells; Patients; Primary Research; Prognosis; Proteins; Sarcoma; Signal transduction; Software; TOR protein; Tumors; United States > US; Grand Island New York; AMPK; AKT; Osteosarcoma; Cisplatin; Cordycepin
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-021-02411-y

Osteosarcoma is the most common primary bone tumor in children and adolescents. However, some patients with osteosarcoma develop resistance to chemotherapy, leading to a poor clinical prognosis. Hence, effective therapeutic agents that can improve the response to chemotherapy drugs to improve the prognosis of patients with osteosarcoma are urgently needed. Cordycepin has recently emerged as a promising antitumor drug candidate. This study aims to explore the effect of cordycepin in suppressing osteosarcoma in vivo and in vitro and the synergistic effect of cordycepin combined with cisplatin and to demonstrate the underlying molecular mechanism. CCK-8 assay was performed to investigate the inhibition effect of cordycepin combined with cisplatin in osteosarcoma cell lines. The colony formation and invasion abilities were measured by colony formation assay and Transwell assay. Osteosarcoma cells apoptosis was detected by flow cytometry. Western blot analysis were used to detect the expression of cell apoptosis-related proteins and AMPK and AKT/mTOR signaling pathway-related proteins. Finally, we performed the in vivo animal model to further explore whether cordycepin and cisplatin exert synergistic antitumor effects. Notably, we found that treatment with cordycepin inhibited cell proliferation, invasion, and induced apoptosis in osteosarcoma cells in vitro and in vivo. Moreover, the combination of cordycepin and cisplatin led to marked inhibition of osteosarcoma cell proliferation and invasion and promoted osteosarcoma cell apoptosis in vitro and in vivo. Mechanistically, we demonstrated that cordycepin enhanced the sensitivity of osteosarcoma cells to cisplatin by activating AMPK and inhibiting the AKT/mTOR signaling pathway. In brief, this study provides comprehensive evidence that cordycepin inhibits osteosarcoma cell growth and invasion and induces osteosarcoma cell apoptosis by activating AMPK and inhibiting the AKT/mTOR signaling pathway and enhances the sensitivity of osteosarcoma cells to cisplatin, suggesting that cordycepin is a promising treatment for osteosarcoma.